Wealthy Women at Higher Risk of Melanoma
It appears that wealthier White women may be at a higher risk of melanoma than less affluent women. These findings were recently published in the Archives of Dermatology. Melanoma is the most deadly...
View ArticleSylatron Approved for Melanoma
The US Food and Drug Administration has approved Sylatron™ (peginterferon alfa-2b) for the treatment of melanoma. Melanoma is the most deadly type of skin cancer. Each year in the United States, there...
View ArticleBRAF Inhibitor Improves Melanoma Survival
Compared with standard chemotherapy, the investigational targeted therapy vemurafenib (also known as PLX4032) delayed the progression of advanced melanoma and improved overall survival. The results of...
View ArticleYervoy Plus Chemotherapy Improves Survival with Advanced Melanoma
Among patients with previously untreated, advanced melanoma, the addition of Yervoy™ (ipilimumab) to chemotherapy improved overall survival. The results of this Phase III clinical trial were presented...
View ArticleAddition of Experimental Vaccine to IL-2 Improves Melanoma Outcomes
Among patients with advanced melanoma, the addition of an experimental anticancer vaccine to treatment with interleukin-2 (IL-2) improved response rates and progression-free survival. These results...
View ArticleSentinel Node Biopsy Safe and Effective for Melanomas on Head and Neck
Although the head and neck region is complex and delicate, sentinel lymph node biopsy for melanomas of the head or neck appears to be safe and effective. These results were published in Cancer. Skin...
View ArticleZelboraf (Vemurafenib) Approved for Melanoma
The targeted therapy Zelboraf™ (vemurafenib) has been approved by the US Food and Drug Administration (FDA) for the treatment of melanomas that carry a common mutation in the BRAF gene. Of the more...
View ArticleMelanoma Drug Accelerates Secondary Skin Cancers In Some Patients
Zelboraf® (vemurafenib) improves outcomes among patients with advanced melanoma that harbors a BRAF gene mutation, but also accelerates the development of squamous cell carcinoma in some patients. A...
View ArticleNew Targeted Therapies Show Promise in Advanced Melanoma
Two new targeted therapies—trametinib and dabrafenib—show promise in the treatment of advanced melanoma, either improving survival or delaying disease progression, according to the results of two...
View ArticleAdjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma
Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published...
View ArticleIntermittent Zelboraf Treatment in Patients with Melanoma May Prevent...
Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by...
View ArticleAnti-PD-1 Drugs Promising for Advanced Melanoma
In Phase I clinical trials, investigational drugs that target a protein known as PD-1 are showing promise for the treatment of advanced melanoma. Results from two of the trials were presented at the...
View ArticleInvestigational Melanoma Drug Shrinks Tumors in Phase III Trial
In a Phase III clinical trial, the investigational drug T-VEC (talimogene laherparepvec) produced durable responses in people with advanced melanoma. These results were presented at the 2013 Annual...
View ArticleMelanoma More Deadly in Young White Men than Women
Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA...
View ArticleYervoy Shows Long-Term Survival Advantage in Advanced Melanoma
Patients with advanced melanoma have lived as long as ten years when treated with the immunologic therapy Yervoy® (ipilimumab), according to pooled data presented at the ESMO 2013 Congress of the...
View ArticleFDA Approves Mekinist in Combination with Tafinlar for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) to treat patients with advanced melanoma. Of the more than one million new...
View ArticleT-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma
The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a...
View ArticleEnzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor...
In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well...
View ArticleStudy of Combination Therapy in Cutaneous Melanoma Stopped Early to Allow...
An Independent Data Monitoring Committee recently recommended that a clinical study of the combination treatment Mekinist™ (trametinib) plus Tafinlar™ (dabrafenib) versus Zelboraf® (vemurafenib) for...
View ArticleInvestigational Drug Pembrolizumab Shows Anticancer Activity in Advanced...
Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy®...
View Article
